JP2009544718A5 - - Google Patents

Download PDF

Info

Publication number
JP2009544718A5
JP2009544718A5 JP2009521907A JP2009521907A JP2009544718A5 JP 2009544718 A5 JP2009544718 A5 JP 2009544718A5 JP 2009521907 A JP2009521907 A JP 2009521907A JP 2009521907 A JP2009521907 A JP 2009521907A JP 2009544718 A5 JP2009544718 A5 JP 2009544718A5
Authority
JP
Japan
Prior art keywords
cell adhesion
pharmaceutical composition
sequence
filamentous bacteriophage
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009521907A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009544718A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/073858 external-priority patent/WO2008011503A2/en
Publication of JP2009544718A publication Critical patent/JP2009544718A/ja
Publication of JP2009544718A5 publication Critical patent/JP2009544718A5/ja
Pending legal-status Critical Current

Links

JP2009521907A 2006-07-21 2007-07-19 タンパク質の繊維性封入体または凝集体の細胞内形成に関連する疾患を処置するための接着タンパク質からのペプチドをディスプレイするファージの使用 Pending JP2009544718A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83222906P 2006-07-21 2006-07-21
PCT/US2007/073858 WO2008011503A2 (en) 2006-07-21 2007-07-19 Use of a phage displaying a peptide from an adhesion protein for treating a disease associated with intracellular formation of protein fibrillar inclusions or aggregates

Publications (2)

Publication Number Publication Date
JP2009544718A JP2009544718A (ja) 2009-12-17
JP2009544718A5 true JP2009544718A5 (https=) 2010-07-29

Family

ID=38957610

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009521907A Pending JP2009544718A (ja) 2006-07-21 2007-07-19 タンパク質の繊維性封入体または凝集体の細胞内形成に関連する疾患を処置するための接着タンパク質からのペプチドをディスプレイするファージの使用

Country Status (8)

Country Link
US (1) US20090324554A1 (https=)
EP (1) EP2054515B1 (https=)
JP (1) JP2009544718A (https=)
CN (1) CN101553567A (https=)
AT (1) ATE541038T1 (https=)
AU (1) AU2007275258A1 (https=)
CA (1) CA2659032A1 (https=)
WO (1) WO2008011503A2 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009072578A1 (ja) * 2007-12-04 2009-06-11 Sapporo Breweries Limited 骨吸収抑制剤
EP2303315A1 (en) * 2008-05-22 2011-04-06 Ramot at Tel Aviv University Ltd. Method for treating disease characterized by plaque
NZ592928A (en) * 2008-11-24 2012-12-21 Univ Ramot Method for treating parkinson' s disease using filamentous bacteriophage
WO2012125555A1 (en) 2011-03-11 2012-09-20 Ramot At Tel-Aviv University Ltd. Method for treating neurodegenerative tauopathy
WO2012142622A1 (en) * 2011-04-15 2012-10-18 Molecular Transfer, Inc. Agents for improved delivery of nucleic acids to eukaryotic cells
EP2736522A1 (en) 2011-07-27 2014-06-04 Neurophage Pharmaceuticals, Inc. Process for the production of filamentous bacteriophage
WO2013022717A1 (en) 2011-08-05 2013-02-14 Neurophage Pharmaceuticals, Inc. Pure filamentous bacteriophage and methods of producing same
CA2857539C (en) 2011-11-29 2021-08-03 Neurophage Pharmaceuticals, Inc. Bacteriophage gene 3 protein compositions and use as amyloid binding agents
DK2906235T3 (en) 2012-10-02 2017-09-25 Proclara Biosciences Inc USE OF P3 OF BACTERIOPHAGIC FUSION PROTEINS AS AMYLOID BINDING AGENTS
AU2014274253B2 (en) 2013-05-28 2018-06-14 Proclara Biosciences, Inc. Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity
CN104258372B (zh) * 2014-09-25 2017-01-25 中山大学 Rgd三肽在制备治疗阿尔茨海默症药物中的用途
BR112017011530A2 (pt) 2014-12-03 2018-03-13 Proclara Biosciences Inc polipeptídeos que compreendem uma sequência de aminoácidos g3p de bacteriófago modificada sem sinal de glicosilação
CN106800590B (zh) * 2015-11-25 2021-04-09 杭州智鹤丹谷生物医药有限公司 一种结合多种淀粉样蛋白单体和聚集体的多肽及其应用
WO2018215831A2 (en) * 2017-05-22 2018-11-29 National Hellenic Research Foundation Macrocyclic modulators of disease associated protein misfolding and aggregation
CA3076473A1 (en) * 2017-09-20 2019-03-28 Council Of Scientific And Industrial Research Novel peptide as potent inhibitor of protein aggregation
WO2022073127A1 (en) * 2020-10-07 2022-04-14 Tatum Bioscience Inc. Live biotherapeutics secreting synthetic bacteriophages in the treatment of cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU784568B2 (en) * 1999-09-03 2006-05-04 Ramot At Tel-Aviv University Ltd Agents and compositions and methods utilizing same useful in diagnosing and/or treating or preventing plaque forming diseases
US20040013647A1 (en) * 1999-09-03 2004-01-22 Ramot At Tel-Aviv University Ltd. Methods and compositions for treating a plaque-forming disease
WO2003076455A2 (en) * 2002-03-05 2003-09-18 Ramot At Tel-Aviv University Ltd. Immunizing composition and method for inducing an immune response against the ss-secretase cleavage site of amyloid precursor protein
WO2006050041A2 (en) * 2004-10-28 2006-05-11 Ramot At Tel Aviv University Ltd. Methods for reducing or inhibiting brain inflammation or for promoting neurogenesis
DK1853285T3 (da) * 2005-02-01 2011-06-27 Univ Ramot Fremgangsmåde til behandling af inflammation forbundet med amyloidaflejringer og hjerneinflammation som involverer aktiverede mikroglia
WO2006100681A2 (en) * 2005-03-25 2006-09-28 Ramot At Tel Aviv University Ltd. Human synthetic single-chain antibodies directed against the common epitope of mutant p53 and their uses

Similar Documents

Publication Publication Date Title
JP2009544718A5 (https=)
JP2012522802A5 (https=)
US20140010885A1 (en) Self-assembling nanoparticle drug delivery system
HRP20170531T1 (hr) Novi terapijski pristupi za liječenje alzheimerove bolesti i povezanih poremećaja putem modulacije angiogeneze
JP2010500399A5 (https=)
JP2005516885A5 (https=)
JP2004115529A5 (https=)
JP2012532874A5 (https=)
BRPI0411986A (pt) forma de dosagem farmacêutica multiparticulada, contendo substáncias peptìdicas ou protéicas ativas formuladas de maneira mucoadesiva, e um método para produzir a dita forma de dosagem farmacêutica
Cryan et al. Increased intracellular targeting to airway cells using octaarginine-coated liposomes: in vitro assessment of their suitability for inhalation
WO2008011503A3 (en) Use of a phage displaying a peptide from an adhesion protein for treating a disease associated with intracellular formation of protein fibrillar inclusions or aggregates
JP2011518179A5 (https=)
JP2014050390A5 (https=)
JP2006506942A5 (https=)
RU2010113962A (ru) Применение фертирелина и дельта-эндорфина в качестве терапевтических средств
Dimitrijevic et al. Application of nanoparticles in psychophysiology and psychiatry research.
US9757428B2 (en) Designed peptides for tight junction barrier modulation
Li et al. Laponite Lights Calcium Flickers by Reprogramming Lysosomes to Steer DC Migration for An Effective Antiviral CD8+ T‐Cell Response
JP2013510832A5 (https=)
DE602005023550D1 (de) Verwendungen eines neurotrophischen Faktors
JP2007506713A (ja) 例えば、抗血管新生活性を有するペプチドおよび治療におけるその適用
JP2014515595A5 (https=)
ZA200400956B (en) Peptidic compounds selectively binding to P-selectin.
US10933113B2 (en) Use of a compound, pharmaceutical composition, and therapeutic method for the treatment or prevention of convulsions
Feyzyab et al. Investigation of the Potency of KALA and REV Cell‐Penetrating Peptides for In Vitro/In Vivo Delivery of an HPV Multiepitope DNA Construct